Regression discontinuity design to evaluate the effect of statins on myocardial infarction in electronic health records.


Journal

European journal of epidemiology
ISSN: 1573-7284
Titre abrégé: Eur J Epidemiol
Pays: Netherlands
ID NLM: 8508062

Informations de publication

Date de publication:
Apr 2023
Historique:
received: 28 06 2022
accepted: 27 02 2023
medline: 11 4 2023
pubmed: 21 3 2023
entrez: 20 3 2023
Statut: ppublish

Résumé

Regression discontinuity design (RDD) is a quasi-experimental method intended for causal inference in observational settings. While RDD is gaining popularity in clinical studies, there are limited real-world studies examining the performance on estimating known trial casual effects. The goal of this paper is to estimate the effect of statins on myocardial infarction (MI) using RDD and compare with propensity score matching and Cox regression. For the RDD, we leveraged a 2008 UK guideline that recommends statins if a patient's 10-year cardiovascular disease (CVD) risk score > 20%. We used UK electronic health record data from the Health Improvement Network on 49,242 patients aged 65 + in 2008-2011 (baseline) without a history of CVD and no statin use in the two years prior to the CVD risk score assessment. Both the regression discontinuity (n = 19,432) and the propensity score matched populations (n = 24,814) demonstrated good balance of confounders. Using RDD, the adjusted point estimate for statins on MI was in the protective direction and similar to the statin effect observed in clinical trials, although the confidence interval included the null (HR = 0.8, 95% CI 0.4, 1.4). Conversely, the adjusted estimates using propensity score matching and Cox regression remained in the harmful direction: HR = 2.42 (95% CI 1.96, 2.99) and 2.51 (2.12, 2.97). RDD appeared superior to other methods in replicating the known protective effect of statins with MI, although precision was poor. Our findings suggest that, when used appropriately, RDD can expand the scope of clinical investigations aimed at causal inference by leveraging treatment rules from everyday clinical practice.

Identifiants

pubmed: 36935439
doi: 10.1007/s10654-023-00982-w
pii: 10.1007/s10654-023-00982-w
doi:

Substances chimiques

Hydroxymethylglutaryl-CoA Reductase Inhibitors 0

Types de publication

Evaluation Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

393-402

Subventions

Organisme : NIA NIH HHS
ID : R56-AG061177
Pays : United States
Organisme : NIA NIH HHS
ID : R56-AG061177
Pays : United States

Informations de copyright

© 2023. Springer Nature B.V.

Références

Cholesterol Treatment Trialists C, Fulcher J, O'Connell R, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397–1405.
Force UPST. Statin use for the primary prevention of cardiovascular disease in adults: US preventive services task force recommendation statement. JAMA. 2022;328(8):746–53.
doi: 10.1001/jama.2022.13044
Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet (Lond Engl). 2002;360(9346):1623–30.
doi: 10.1016/S0140-6736(02)11600-X
Han BH, Sutin D, Williamson JD, et al. Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults: the ALLHAT-LLT randomized clinical trial. JAMA Intern Med. 2017;177(7):955–65.
pubmed: 28531241 pmcid: 5543335 doi: 10.1001/jamainternmed.2017.1442
Venkataramani AS, Bor J, Jena AB. Regression discontinuity designs in healthcare research. BMJ. 2016;352: i1216.
pubmed: 26977086 pmcid: 6884311 doi: 10.1136/bmj.i1216
Wallace J, Jiang K, Goldsmith-Pinkham P, Song Z. Changes in racial and ethnic disparities in access to care and health among US adults at age 65 years. JAMA Intern Med. 2021;181(9):1207–15.
pubmed: 34309621 pmcid: 8314180 doi: 10.1001/jamainternmed.2021.3922
Fukuma S, Iizuka T, Ikenoue T, Tsugawa Y. Association of the national health guidance intervention for obesity and cardiovascular risks with health outcomes among Japanese men. JAMA Intern Med. 2020;180(12):1630–7.
pubmed: 33031512 pmcid: 7536624 doi: 10.1001/jamainternmed.2020.4334
Maciejewski ML, Basu A. Regression discontinuity design. JAMA. 2020;324(4):381–2.
pubmed: 32614409 doi: 10.1001/jama.2020.3822
Desai S, McWilliams JM. Consequences of the 340B drug pricing program. N Engl J Med. 2018;378(6):539–48.
pubmed: 29365282 pmcid: 6073067 doi: 10.1056/NEJMsa1706475
Hutcheon JA, Harper S, Liauw J, Skoll MA, Srour M, Strumpf EC. Antenatal corticosteroid administration and early school age child development: a regression discontinuity study in British Columbia, Canada. PLoS Med. 2020;17(12):e1003435.
pubmed: 33284805 pmcid: 7721186 doi: 10.1371/journal.pmed.1003435
Goulden R, Rowe BH, Abrahamowicz M, Strumpf E, Tamblyn R. Association of intravenous radiocontrast with kidney function: a regression discontinuity analysis. JAMA Intern Med. 2021;181(6):767–74.
pubmed: 33818606 pmcid: 8022267 doi: 10.1001/jamainternmed.2021.0916
Melamed A, Fink G, Wright AA, et al. Effect of adoption of neoadjuvant chemotherapy for advanced ovarian cancer on all cause mortality: quasi-experimental study. BMJ (Clin Res Ed). 2018;360: j5463.
doi: 10.1136/bmj.j5463
Chen S, Sudharsanan N, Huang F, Liu Y, Geldsetzer P, Bärnighausen T. Impact of community based screening for hypertension on blood pressure after two years: regression discontinuity analysis in a national cohort of older adults in China. BMJ. 2019;366:l4064.
Sudharsanan N, Chen S, Barnighausen T, Geldsetzer P. The effect of home-based hypertension screening on blood pressure change over time in South Africa. Health Aff (Millwood). 2020;39(1):124–132.
Cattaneo MD, Titiunik R. Regression discontinuity designs. Ann. Rev Econ. 2022;14 (forthcoming).
Hahn J, Todd P, Van der Klaauw W. Identification and estimation of treatment effects with a regression-discontinuity design. Econometrica. 2001;69(1):201–209
Lee DS, Lemieux T. Regression discontinuity designs in economics. J Econ Lit. 2010;48(2):281–355.
doi: 10.1257/jel.48.2.281
Thistlethwaite DL, Campbell DT. Regression-discontinuity analysis: An alternative to the ex post facto experiment. J Educ Psychol. 1960;51:309–317.
Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Brindle P. Performance of the QRISK cardiovascular risk prediction algorithm in an independent UK sample of patients from general practice: a validation study. Heart. 2008;94(1):34–9.
pubmed: 17916661 doi: 10.1136/hrt.2007.134890
Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41–55.
doi: 10.1093/biomet/70.1.41
Smith LM, Lévesque LE, Kaufman JS, Strumpf EC. Strategies for evaluating the assumptions of the regression discontinuity design: a case study using a human papillomavirus vaccination programme. Int J Epidemiol. 2016;46(3):939–49.
pmcid: 5837477
Cattaneo MD, Idrobo N, Titiunik R. A practical introduction to regression discontinuity designs: foundations. Cambridge: Cambridge University Press; 2019.
doi: 10.1017/9781108684606
Blak BT, Thompson M, Dattani H, Bourke A. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care. 2011;19(4):251–5.
pubmed: 22828580
Danaei G, Garcia Rodriguez LA, Fernandez Cantero O, Hernan MA. Statins and risk of diabetes: an analysis of electronic medical records to evaluate possible bias due to differential survival. Diabetes Care. 2013;36(5):1236–40.
pubmed: 23248196 pmcid: 3631834 doi: 10.2337/dc12-1756
Smeeth L, Douglas I, Hall AJ, Hubbard R, Evans S. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol. 2009;67(1):99–109.
pubmed: 19006546 pmcid: 2668090 doi: 10.1111/j.1365-2125.2008.03308.x
Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf. 2007;16(4):393–401.
pubmed: 17066486 doi: 10.1002/pds.1335
Maguire A, Blak BT, Thompson M. The importance of defining periods of complete mortality reporting for research using automated data from primary care. Pharmacoepidemiol Drug Saf. 2009;18(1):76–83.
pubmed: 19065600 doi: 10.1002/pds.1688
Ruigomez A, Martin-Merino E, Rodriguez LA. Validation of ischemic cerebrovascular diagnoses in the health improvement network (THIN). Pharmacoepidemiol Drug Saf. 2010;19(6):579–85.
pubmed: 20131328 doi: 10.1002/pds.1919
Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care. 2004;12:171–7.
pubmed: 15606990
Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991;121(1 Pt 2):293–8.
pubmed: 1985385 doi: 10.1016/0002-8703(91)90861-B
Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ. 2007;335(7611):136.
pubmed: 17615182 pmcid: 1925200 doi: 10.1136/bmj.39261.471806.55
Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ. 2008;336(7659):1475–82.
pubmed: 18573856 pmcid: 2440904 doi: 10.1136/bmj.39609.449676.25
Garcia Rodriguez LA, Perez GS. Use of the UK general practice research database for pharmacoepidemiology. Br J Clin Pharmacol. 1998;45(5):419–25.
pubmed: 9643612 pmcid: 1873548 doi: 10.1046/j.1365-2125.1998.00701.x
Dave S, Petersen I. Creating medical and drug code lists to identify cases in primary care databases. Pharmacoepidemiol Drug Saf. 2009;18(8):704–7.
pubmed: 19455565 doi: 10.1002/pds.1770
Chisholm J. The Read clinical classification. BMJ. 1990;300(6732):1092.
pubmed: 2344534 pmcid: 1662793 doi: 10.1136/bmj.300.6732.1092
Calonico S, Cattaneo MD, Titiunik R. Robust nonparametric confidence intervals for regression-discontinuity designs. Econometrica. 2014;82(6):2295–326.
doi: 10.3982/ECTA11757
Calonico S, Cattaneo MD, Titiunik R. Optimal data-driven regression discontinuity plots. J Am Stat Assoc. 2015;110(512):1753–69.
doi: 10.1080/01621459.2015.1017578
Imbens G, Kalyanaraman K. Optimal bandwidth choice for the regression discontinuity estimator. Rev Econ Stud. 2011;79(3):933–59.
doi: 10.1093/restud/rdr043
Calonico S, Cattaneo MD, Farrell MH, Titiunik R. Regression discontinuity designs using covariates. Rev Econ Stat. 2019;101(3):442–51.
doi: 10.1162/rest_a_00760
Calonico S, Cattaneo MD, Farrell MH, Titiunik R. rdrobust: software for regression-discontinuity designs. Stata J. 2017;17(2):372–404.
doi: 10.1177/1536867X1701700208
Cholesterol Treatment Trialists C, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681.
Geneletti S, O’Keeffe AG, Sharples LD, Richardson S, Baio G. Bayesian regression discontinuity designs: incorporating clinical knowledge in the causal analysis of primary care data. Stat Med. 2015;34(15):2334–52.
pubmed: 25809691 pmcid: 4856212 doi: 10.1002/sim.6486
O’Keeffe AG, Geneletti S, Baio G, Sharples LD, Nazareth I, Petersen I. Regression discontinuity designs: an approach to the evaluation of treatment efficacy in primary care using observational data. BMJ (Clinical research ed). 2014;349:g5293.
pubmed: 25199521
Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6(3):208–15.
pubmed: 22658145 doi: 10.1016/j.jacl.2012.03.003
Lauffenburger JC, Robinson JG, Oramasionwu C, Fang G. Racial/Ethnic and gender gaps in the use of and adherence to evidence-based preventive therapies among elderly Medicare Part D beneficiaries after acute myocardial infarction. Circulation. 2014;129(7):754–63.
pubmed: 24326988 doi: 10.1161/CIRCULATIONAHA.113.002658
Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288(4):462–7.
pubmed: 12132976 doi: 10.1001/jama.288.4.462
Adams J, Ryan V, White M. How accurate are Townsend Deprivation Scores as predictors of self-reported health? A comparison with individual level data. J Public Health (Oxf). 2005;27(1):101–6.
pubmed: 15564276 doi: 10.1093/pubmed/fdh193
Yusuf S, Bosch J, Dagenais G, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374(21):2021–31.
pubmed: 27040132 doi: 10.1056/NEJMoa1600176
Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735–42.
pubmed: 20167359 doi: 10.1016/S0140-6736(09)61965-6
Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207.
pubmed: 18997196 doi: 10.1056/NEJMoa0807646
Officers A, Coordinators for the ACRGTA, Lipid-Lowering Treatment to Prevent Heart Attack T. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288(23):2998–3007.

Auteurs

Michelle C Odden (MC)

Department of Epidemiology and Population Health, Stanford University, Stanford, CA, USA. modden@stanford.edu.
Department of Epidemiology and Population Health, Stanford University School of Medicine, 1701 Page Mill Rd., Palo Alto, CA, 94304, USA. modden@stanford.edu.

Adina Zhang (A)

Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.

Neal Jawadekar (N)

Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.

Annabel Tan (A)

Department of Epidemiology and Population Health, Stanford University, Stanford, CA, USA.

Andrew E Moran (AE)

Department of Medicine, Columbia University, New York, NY, USA.

M Maria Glymour (MM)

Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.

Carol Brayne (C)

Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

Adina Zeki Al Hazzouri (A)

Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.

Sebastian Calonico (S)

Department of Health Policy and Management, Columbia University, New York, NY, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH